Brasseur R, Carlier M B, Laurent G, Claes P J, Vanderhaeghe H J, Tulkens P M, Ruysschaert J M
Biochem Pharmacol. 1985 Apr 1;34(7):1035-47. doi: 10.1016/0006-2952(85)90607-0.
Aminoglycoside antibiotics induce a lysosomal phospholipidosis in kidney proximal tubules after conventional therapy in animals and man. We have previously demonstrated that these drugs bind to negatively charged phospholipid bilayers at acid pH and inhibit the activity of lysosomal acid phospholipases in vitro and in vivo. A combined biochemical and conformational study [Brasseur et al., Biochem. Pharmac. 33, 629 (1984)] showed major and consistent differences between 6 aminoglycosides in current clinical use with respect to the stability of the complexes they form with phosphatidylinositol, their inhibitory potency towards the activity of lysosomal phospholipases and their current toxicity ranking (e.g. gentamicin greater than amikacin greater than streptomycin). In the present study we have extended this approach to experimental derivatives of streptomycin. The derivatives examined were: dihydrostreptomycin, dideguanyldihydrostreptomycin, streptomycylamine, dideguanylstreptomycylamine, N-butyl- and N-benzyl-dideguanylstreptomycylamine. These compounds were examined for (i) their binding to negatively charged liposomes, measured by gel permeation on Sepharose 4B; (ii) their interactions with phosphatidylinositol assessed by semi-empirical conformational analysis and (iii) their inhibitory effect on the activities of lysosomal phospholipases towards phosphatidylcholine present in negatively charged liposomes. Streptomycin and gentamicin were also used as reference compounds with low and high affinity (and inhibitory potency), respectively. Our observations can be summarized as follows: (i) the replacement of the aldehyde in the streptose ring by a methylamino group strikingly changes the conformation of the molecule, allowing a better interaction with phosphatidylinositol. Thus, streptomycylamine binds much more tightly to phospholipid bilayers and shows a higher inhibitory potency towards phospholipase activity, as compared to streptomycin. The conformational analysis shows, however, that this effect is only partially due to the additional cationic charge carried by streptomycylamine. Other modifications of the streptomycin molecule, such as the replacement of the guanidinium groups by aminogroups or the addition of hydrophobic moieties (butyl or benzyl groups) to the streptose do not markedly further strengthen the interactions of the molecule with phosphatidylinositol. (ii) Even though some derivatives (e.g. dideguanylstreptomycylamine) bind as tightly to phospholipids as gentamicin, they remain much less inhibitory towards lysosomal phospholipases.(ABSTRACT TRUNCATED AT 400 WORDS)
氨基糖苷类抗生素在动物和人类接受常规治疗后会在肾近端小管中诱发溶酶体磷脂沉积症。我们之前已经证明,这些药物在酸性pH值下与带负电荷的磷脂双层结合,并在体外和体内抑制溶酶体酸性磷脂酶的活性。一项结合生物化学和构象研究[布拉瑟尔等人,《生物化学与药理学》33, 629 (1984)]表明,目前临床使用的6种氨基糖苷类药物在它们与磷脂酰肌醇形成的复合物的稳定性、对溶酶体磷脂酶活性的抑制效力以及它们当前的毒性排名(例如庆大霉素大于阿米卡星大于链霉素)方面存在主要且一致的差异。在本研究中,我们将这种方法扩展到链霉素的实验性衍生物。所研究的衍生物有:双氢链霉素、双去甲胍基双氢链霉素、链霉胺、双去甲胍基链霉胺、N -丁基 - 和N -苄基 - 双去甲胍基链霉胺。对这些化合物进行了以下检测:(i) 通过在琼脂糖4B上的凝胶渗透法测量它们与带负电荷脂质体的结合;(ii) 通过半经验构象分析评估它们与磷脂酰肌醇的相互作用;(iii) 它们对溶酶体磷脂酶作用于带负电荷脂质体中磷脂酰胆碱活性的抑制作用。链霉素和庆大霉素也分别作为低亲和力和高亲和力(以及抑制效力)的参考化合物使用。我们的观察结果可总结如下:(i) 链霉糖环中的醛基被甲氨基取代显著改变了分子的构象,使其能更好地与磷脂酰肌醇相互作用。因此,与链霉素相比,链霉胺与磷脂双层的结合更紧密,对磷脂酶活性的抑制效力更高。然而,构象分析表明,这种效应仅部分归因于链霉胺所携带的额外阳离子电荷。链霉素分子的其他修饰,如胍基被氨基取代或在链霉糖上添加疏水基团(丁基或苄基),并未明显进一步增强分子与磷脂酰肌醇的相互作用。(ii) 尽管一些衍生物(如双去甲胍基链霉胺)与磷脂的结合程度与庆大霉素一样紧密,但它们对溶酶体磷脂酶的抑制作用仍然小得多。